Efficacy and safety of tretinoin 0.05% cream to prevent hyperpigmentation during narrowband UV-B phototherapy in patients with facial vitiligo: a randomized clinical trial.
J Dermatolog Treat
; 33(3): 1738-1741, 2022 May.
Article
em En
| MEDLINE
| ID: mdl-32869680
ABSTRACT
BACKGROUND:
Narrowband UV-B (NBUVB) phototherapy is the mainstay of vitiligo treatment, but hyperpigmentation is one of the limitations. Meanwhile, topical tretinoin is effective against pigmentary disorders.OBJECTIVE:
To determine whether tretinoin 0.05% cream would prevent hyperpigmentation when patients with facial vitiligo underwent phototherapy.METHODS:
A randomized, controlled, split-face trial was conducted. Adult patients with stable, non-segmental facial vitiligo were enrolled. The left/right sides of the face were randomly allocated to receive either topical tretinoin 0.05% cream or moisturizer twice daily. The entire face was subjected to NBUVB phototherapy twice weekly for 12 weeks. The degree of hyperpigmentation was assessed as the delta L* (brightness) value of the darkest spot in each side of the face at baseline and every 4 weeks. The degree of repigmentation was assessed.RESULTS:
Twenty-five patients were enrolled; 21 completed the study. The delta L* value was significantly different between the two groups -0.5% in the tretinoin group and -8.7% in the control group at 12 weeks (p = .002). Marked repigmentation was achieved in 15 patients of both groups.CONCLUSIONS:
Tretinoin 0.05% cream prevented hyperpigmentation during NBUVB phototherapy in patients with facial vitiligo, and did not compromise the overall treatment response. TRIAL REGISTRATION ClinicalTrials.gov NCT03933774.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Terapia Ultravioleta
/
Vitiligo
/
Hiperpigmentação
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article